Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with lymphoblastic leukemia;INTRAZELLULARE RETENTION VON CYTARABIN-TRIHOSPHAT (ARA-CTP) IN BLASTEN VON KINDERN MIT AKUTER LYMPHOBLASTISCHER LEUKAMIE

Klinische Padiatrie

Volumn 208, Issue 4, 1996, Pages 151-159

  Schiller, Meinhard ^a   Hohenlöchter, Barbara ^a   Schulze Westhoff, Petra ^a   Zimmermann, Martin ^a   Ritter, Jörg ^a   Jürgens, Herbert ^a   Boos, Joachim ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cellular pharmacology; Cytarabine; Cytarabine triphosphate; Leukemia; T ALL

Indexed keywords

CYTARABINE; CYTARABINE TRIPHOSPHATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CELL LEVEL; CHILDHOOD DISEASE; CLINICAL ARTICLE; DISEASE SEVERITY; HUMAN; IN VITRO STUDY; LABORATORY TEST; RISK ASSESSMENT; ACUTE LYMPHOCYTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; B CELL LEUKEMIA; BLAST CELL CRISIS; BLOOD; BONE MARROW; CHILD; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; INFANT; MALE; METABOLISM; MORTALITY; PRESCHOOL CHILD; PROGNOSIS; REMISSION;

ADOLESCENT; ADULT; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; BLAST CRISIS; BONE MARROW; CHILD; CHILD, PRESCHOOL; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; LEUKEMIA, PRE-B-CELL; MALE; PROGNOSIS; REMISSION INDUCTION;

EID: 0030187372     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1046466     Document Type: Article

References (57)

1. Abe, I., S. Saito, K. Hori, M. Suzuki, H. Sato: Role of dephosphorylation in accumulation of 1-β-D arabinofuranosylcytosine-5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res. 42 (1982) 2846-2851
2. Avramis, V. I., R. Biener, M. Krailo, J. Finklestein, L. Ettinger, M. Willoughby, S. E. Sieges, J. S. Holcenberg: Biochemical pharmacology of high dose 1-β-D-arabinofuranosylcytosine in childhood acute leukemia. Cancer Res. 47 (1987) 6786-6792
3. Avramis, V. I., K. I. Weinberg, J. K. Sato, C. Lenarsky, M. Willoughby, T. D. Coates, M. F. Ozkaynak, R. Parkman: Pharmacology studies of 1-β-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemical optimal regimen of loading bolus plus continuous infusion of the drug. Cancer Res. 49 (1989) 241-247
4. Barredo, J. C., T. W. Synold, J. Laver, M. V. Relling, C. H. Pui, D. G. Priest, W. E. Evans: Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84(2) (1994) 564-569
5. Bekassy, A. N., J. Liliemark, S. Garwicz, T. Wiebe, H. Gullikson, C. Peterson: Pharmacokinetics of cytosine arabinoside in cerebrospinal fluid and of its metabolite in leukemic cells. Med. Pediatr. Oncol. 18 (1990) 136-142
6. Boos, J.: A simple isocratic ion-pair high-performance liquid chromatographic determination of 1-β-D arabinofuranosylcytosine 5′-triphosphate for intracellular drug-monitoring and in vitro incubation assays. J. Pharm. Biomed. Anal. 9 (1991) 47-52
7. Boos, J.: Intracellular kinetics of Ara-CTP in leukemic cells from children. Klin. Pharmakol. akt. 3 (1992) 46-47
8. Boos, J.: 1st die Pharmacokinetik von Cylarabin klinisch relevant? Klin. Pädiatr. 204 (1992) 198-203
9. Boos, J.: Klinisch-pharmakologische Untersuchungen der Cytostatika Etoposid und Cytarabin sowie ihrer Kombination in Rahmen der pädiatrisch-onkologischen Therapieprotokolle. W. Zuckschwerdt Verlag, München-Bern-Wien-New York 1995 (Aktuelle Onkologie 85)
10. Boos, J., M. Schiller, B. Pröbsting, U. Creutzig, J. Ritter: Intracellular retention of cytosine-arabinoside triphosphate in leukemic blast cells from children. In: Acute Leukemias V - Experimental Approaches and Managment of Refractory Diseases. Hiddemann et al. (eds). Springer Verlag, Berlin Heidelberg (1996) 50-53
11. Boos, J., B. Hohenlöchter, P. Schulze-Westhoff, M. Schiller, M. Zimmermann, U. Creutzig, J. Ritter, H. Jürgens: Intracellulur retention of cytosine-arabinoside-triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Med. Pediatr. Oncol. (1996 in press)
12. Breithaupt, H., H. Pralle, T. Eckhardt, M. v. Hattingberg, J. Schick, H. Löffler: Clinical results and pharmakokinetics of high-dose cytosine arabinoside. Cancer 50 (1882) 1248-1257
13. Creutzig, U., J. Kitter, G. Schellong for the AML-BFM Study Group. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. Blood 75 (1990) 1932-1940
14. Creutzig, U., J. Ritter, M. Zimmermann, G. Schellong: Does cranial irridiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the childhood acute myelogenous leukemia study BFM-87. J. Clin. Oncol. 11 (1993) 279-286
15. Early, A. P., H. D. Preisler, H. Slocum, Y. M. Rustum: A pilot study of high dose 1-β-D arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology. Cancer Res. 42 (1982) 1587-1594
16. Estey, E. H., M. J. Keating, K. B. McCredie, E. J. Freireich, W. Plunkett: Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4 (1990) 95-99
17. Gandhi, V., W. Plunkett: Cell cycle-specific metabolism of arabinosyl nucleotides in K562 human leukemia cells. Cancer Chemother. Pharmacol. 31 (1992) 11-17
18. Heinemann, V. E., Estey, M. J. Keating, W. Plunkett: Patient-specific dose rate for continuous infusion high dose cytarabine in relapsed acute myelogenous leukemia. J. Clin. Oncol. 7 (1989) 622-628
19. Henze, G., R. Fengler, R. Hartmann, for the BFM Relapse Study Group: Chemotherapy for relapsed childhood acute lymphohlastic leukemia: Results of the BFM Study Group. In: Büchner, T., G. Schellong, W. Hiddemann, J. Ritter (eds.): Haematology and Blood Transfusion, Acute Leukemias IV. Springer, Berlin Heidelberg 36 (1994) 374-383
20. Hiddemann, W.: Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens. Ann. Hematol. 62 (1991) 119-128
21. Hiddemann, W., E. Schleyer, M. Unterhalt, M. Z̈hlsdorf, C. Rolf, C. Reuter, U. Kewer, C. Uhrmeister, B. Wörmann, T. Büchner: Differences in the intracellular pharmacokinetics of cytosine arabinoside (AraC) between circulating leukemic blasts and normal mononuclear blood cells. Leukemia 6 (1992) 1273-1280
22. Jamieson, G. P., M. B. Snook, J. S. Wiley: Saturation of intracellular cytosine arabinoside triphosphate accumulation in human leukemic blast cells. Leuk. Res. 14(5) (1990) 475-479
23. Kanti, R. R., J. F. Holland, O. J. Glidewell, V. Weinberg, K. Brunner, J. P. Obrecht, H. Preisler, I. W. Nawabi, D. Prager, R. W. Carey, M. R. Cooper, F. Haurani, J. E. Hutchinson, R. T. Silver, G. Falkson, P. Wiernik, H. C. Hoagland, C. D. Bloomfiels, G. W. James, A. Gottlieb, S. V. Ramanan, J. Blom, N. I. Nissen, A. Bank, R. R. Ellison, F. Kung, P. Henry, O. R. McIntyre, S. K. Kaan: Treatment of acute myelocytic leukemia: A study by cancer and leukemia Group B. Blood 58 (1981) 1203-1212
24. Kaplan, E. I., P. Meier: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
25. Kawasaki, H., M. Higashigawa, T. Ohkubo, H. Kamiya, M. Sakurai: Relationship between intracellular dCTP/Ara-CTP ratio and cytotoxic effect of Ara-C. Adv. Exp. Med. Biol. 253 B (1986) 364-374
26. Kessel, D., T. C. Hall, I. Wodinsky: Transport and phosphorylation as factors in the antitumor action of cytosine arabinoside. Science 156 (1967) 1240-1241
27. Kufe, D., D. Spriggs, D. Munroe: Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64 (1984) 54-58
28. Langermann, H. J., G. Henze, M. Wulf, H. Riehm: Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindesalter: prognostische Bedeutung und praktische Anwendung. Klin. Pädiatr. 194 (1982) 209-213
29. Lauer, S. J., D. Pinkel, G. R. Buchanan, P. Sartain, J. M. Cornel, R. Krance, L. D. Borella, J. T. Casper, L. E. Kun, R. G. Hoffman, B. M. Camitta: Cytosine arabinoside/cyclophosphamide pulses during continuation therapy for childhood acute lymphoblastic leukemia - potential selective effect in T-cell leukemia. Cancer 60 (1987) 2366-2371
30. Lie, S. O., S. Slördahl: High-dose cytosine arabinoside in the treatment of childhood malignancies. Semin. Oncol. 12 (Suppl 3) (1985) 160-165
31. Mantel, N.: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50 (1966) 163-170
32. Momparler, R. L., N. Onetto-Pothier, D. V. Bouffard, L. F. Momparler: Cellular pharmacology of 1-β-D arabinofuranosylcytosine in human myeloid, B-lymphoid and T-lymphoid leukemic cells. Cancer Chemother. Pharmacol. 27 (1990) 141-146
33. Muus, P., A. Drenthe-Schonk, C. Haanen, H. Wessels, P. Linssen: InVitro studies on phosphorylation and dephosphorylation of cytosine arabinoside in human leukemic cells. Leuk. Res. 11 (1987) 319-325
34. Peters, W. G., L. P. Colly, R. Willemze: High-dose cytosine arabinoside: pharmacological and clinical aspects. Blut 56 (1988) 1-11
35. Plunkett, W., S. Iacoboni, E. Estey, L. Danhauser, J. O. Liliemark, M. J. Keating: Pharmacologically directed ara-C therapy for refractory leukemia. Semin. Oncol. 12 (Suppl. 1) (1985) 20-30
36. Plunkett, W., S. Iacoboni, M. Keating: Cellular pharmacology and optimal therapeutic concentrations of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-β-D-arabinofuranosylcytkosine. Scand. J. Haematol. 34 (Suppl. 44) (1986) 51-59
37. Plunkett, W., J. O. Liliemark, T. M. Adams, B. Nowak, E. Estey, H. Kantarjian, M. J. Keating: Saturation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-D-arabinofuranosylcytosine therapy. Cancer Res. 47 (1987) 3005-3011
38. Preisler, H. D., Y. M. Rustum, N. Azarnia, R. Priore: Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside. Cancer Chemother. Pharmacol. 19 (1987) 69-74
39. Pui, C. H.: Childhood leukemias. N. Engl. J. Med. 332(24) (1995) 1618-1630
40. Reiter, A., M. Schruppe, W. D. Ludwig, W. Hiddemann, S. Sauter, G. Henze, M. Zimmermann, F. Lampert, W. Havers, D. Niethammer, E. Odenwald, J. Ritter, G. Mann, K. Welte, H. Gadner, H. Riehm: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84(9) (1994) 3122-3133
41. Relling, M. V., D. Fairclough, D. Ayers, W. R. Crom, J. E. Rodman, C. H. Pui, W. E. Evans: Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J. Clin. Oncol. 12(8) (1994) 1667-1672
42. Richel, D. J., L. P. Colly, M. W. Arentsen-Honders, C. W. J. Starrenburg, R. Willemze: Deoxycytidine kinase, thymidine kinase and cytidine deaminase and the formation of Ara-CTP in leukemic cells in different phases of the cell cycle. Leuk. Res. 14 (1990) 363-369
43. Riehm, H., A. Reiter, M. Schrappe, F. Berthold, R. Dopfer, H. Gerein, R. Ludwig, J. Riller, B. Stollmann, G. Henze: The in vivo response on corticoid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83). Klin. Padiatr. 199 (1987) 151-160
44. Riehm, H., H. Gadner, G. Henze, B. Kornhuber, F. Lampert, D. Niethammer, A. Reiter, G. Schellong: Results and significance of six randomized trials in four consecutive ALL-BFM trials. Hematol. Bluttransfus. 33 (1990) 439-450
45. Ritter, J., U. Creutzig, A. Reiter, H. Riehm, G. Schellong: Childhood leukemia: cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany. J. Cancer Res. Clin. Oncol. 116 (1990) 100-103
46. Ross, D., B. Thompson, C. Joneckis, S. Akman, C. Schiffer: Metabolism of Ara-C by blast cells from patients with ANLL. Blood 68 (1987) 76-82
47. Rustum, Y. M., H. D. Preisler: Correlation between leukemic cell retention of 1-β-D-arabinofuranosylcytosine 5′-Triphosphate and response to therapy. Cancer Res. 39 (1979) 42-49
48. Rustum, Y. M., H. K. Slocum, G. Wang, D. Bakshi, E. Kelly, D. Buscaglia, C. Wrzosek, A. P. Early, H. D. Preisler: Relationship between plasma ara-C and intracellular ara-CTP pools under conditions of continuous infusion and high-dose ara-C treatment. Med. Pediatr. Oncol. Suppl. 1 (1982) 33-43
49. Rustum, Y. M., C. Riva, H. D. Preslier: Pharmacokinetic parameters of 1-β-D-arabinofuranosylcytosine and their relationship to intracellular metabolism of ara-C, toxicity and response of patients with acute non-lymphocytic leukemia treated with conventional and high-dose ara-c. Semin. Oncol. 14 Suppl. 1 (1987) 141-148
50. Schrappe, M., A. Reiter, S. Sauter, W. D. Ludwig, B. Wörmann, J. Harbott, C. Bender-Götze, W. Dörffel, R. Dopfer, E. Frey, W. Havers, G. Henze, J. Kühl, R. Richter, J. Ritter, J. Treuner, F. Zintl, E. Odenwald, K. Welte, H. Gadner, H. Riehm: Konzeption und Zwischenergebnis der Therapiestudie ALL-BFM 90 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: Die Bedeutung des initialen Therapieansprechens in Blut und Knochenmark. Klin. Pädiatr. 206 (1994) 208-221
51. Slevin, M. L., E. M. Piall, G. W. Aherne, A. Johnston, T. A. Lister: The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med. Pediatr. Oncol. Suppl. 1 (1982) 157-168
52. Slevin, M. L., E. M. Piall, G. W. Aherne, V. J. Harvey, A. Johnston, T. A. Lister: Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J. Clin. Oncol. 1 (1983) 546-551
53. Synold, T. W., M. V. Relling, J. M. Boyett, G. K. Rivera, J. T. Sandlund, H. Mahmoud, W. M. Crist, C. H. Pui, W. E. Evans: Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J. Clin. Invest. 94(5) (1994) 1996-2001
54. Tanaka, M., S. Yoshida: Efficient formation of cytosine arabinoside-5′-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia. Leuk. Res. 13(10) (1989) 931-936
55. van Prooijen, H. C., A. W. Dekker, K. Punt: The use of intermediate dose cytosine arabinoside (ID ara-C) in the treatment of acute nonlymphocytic leukemia in relapse. Br. J. Haematol. 57 (1984) 291-299
56. White, J. C., J. P. Rathmell, R. L. Capizzi: Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemic cells. J. Clin. Invest. 79 (1987) 380-387
57. Wiley, J. S., S. P. Jones, W. H. Sawyer, A. R. P. Paterson: Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J. Clin. Invest. 69 (1982) 479-489